These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22392136)

  • 1. Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis.
    Shakya N; Sane SA; Haq W; Gupta S
    Parasitol Res; 2012 Aug; 111(2):563-70. PubMed ID: 22392136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
    Sane SA; Shakya N; Haq W; Gupta S
    J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis.
    Shakya N; Sane SA; Vishwakarma P; Gupta S
    Exp Parasitol; 2012 Jul; 131(3):377-82. PubMed ID: 22626518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis.
    Shivahare R; Vishwakarma P; Parmar N; Yadav PK; Haq W; Srivastava M; Gupta S; Kar S
    PLoS One; 2014; 9(4):e94596. PubMed ID: 24732039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
    Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
    Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv.
    Shakya N; Sane SA; Gupta S
    Parasitol Res; 2011 Apr; 108(4):793-800. PubMed ID: 21212980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis.
    Sane SA; Shakya N; Gupta S
    Exp Parasitol; 2011 Feb; 127(2):376-81. PubMed ID: 20846525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
    Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leptin augments protective immune responses in murine macrophages and enhances potential of miltefosine against experimental visceral leishmaniasis.
    Shivahare R; Ali W; Vishwakarma P; Natu SM; Puri SK; Gupta S
    Acta Trop; 2015 Oct; 150():35-41. PubMed ID: 26119043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-activating factor receptor contributes to antileishmanial function of miltefosine.
    Gangalum PR; de Castro W; Vieira LQ; Dey R; Rivas L; Singh S; Majumdar S; Saha B
    J Immunol; 2015 Jun; 194(12):5961-7. PubMed ID: 25980013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Withania somnifera chemotype NMITLI 101R significantly increases the efficacy of antileishmanial drugs by generating strong IFN-γ and IL-12 mediated immune responses in Leishmania donovani infected hamsters.
    Tripathi CD; Kushawaha PK; Sangwan RS; Mandal C; Misra-Bhattacharya S; Dube A
    Phytomedicine; 2017 Jan; 24():87-95. PubMed ID: 28160866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG oligodeoxynucleotide 2006 and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis.
    Gupta S; Sane SA; Shakya N; Vishwakarma P; Haq W
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3461-4. PubMed ID: 21537026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis.
    Gupta S; Ramesh SC; Srivastava VM
    Acta Trop; 2005 Apr; 94(1):41-7. PubMed ID: 15895483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
    Seifert K; Croft SL
    Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral combination of eugenol oleate and miltefosine induce immune response during experimental visceral leishmaniasis through nitric oxide generation with advanced cytokine demand.
    Kar A; Charan Raja MR; Jayaraman A; Srinivasan S; Debnath J; Kar Mahapatra S
    Cytokine; 2021 Oct; 146():155623. PubMed ID: 34144446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
    Escobar P; Yardley V; Croft SL
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
    Vishwakarma P; Parmar N; Yadav PK; Chandrakar P; Kar S
    J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.
    Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF
    Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
    Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
    Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
    Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
    Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.